+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Screening and surveillance of Barrett's esophagus



Screening and surveillance of Barrett's esophagus



Current Gastroenterology Reports 11(3): 195-201



Esophageal adenocarcinoma (EAC) is the most rapidly increasing cancer in the Western world and Barrett's esophagus (BE) is the only known precursor lesion for this lethal cancer. Long-term survival may be improved if EAC is diagnosed early, providing an opportunity for early intervention. Screening for BE in patients with gastroesophageal reflux disease is not routinely recommended; however, if diagnosed, enrollment into a surveillance program may be beneficial. Surveillance of all patients with known BE is probably not cost-effective and factors predictive of BE progression to dysplasia/EAC are poorly understood. Screening and surveillance examinations are also faced with challenges in the endoscopic detection of intestinal metaplasia and dysplasia. Future application of molecular biomarkers may help identify the patients with BE most likely to progress, and the use of novel imaging methods may improve outcomes of BE screening and surveillance.

(PDF emailed within 0-6 h: $19.90)

Accession: 055670378

Download citation: RISBibTeXText

PMID: 19463219

DOI: 10.1007/s11894-009-0031-5


Related references

Screening and surveillance for Barrett esophagus. JAMA Internal Medicine 175(2): 159-160, 2015

How far to go? Screening and surveillance in Barrett's esophagus. American Journal of Managed Care 7(1 Suppl): S19-S26, 2001

Screening for and surveillance of Barrett's esophagus is clinically indicated. Digestive Diseases 25(3): 197-202, 2007

Surveillance and screening for Barrett esophagus and adenocarcinoma. Journal of Clinical Gastroenterology 39(4 Suppl 2): S33-S41, 2005

Barrett's esophagus: novel strategies for screening and surveillance. Therapeutic Advances in Chronic Disease 10: 2040622319837851, 2019

Not all of Barrett's esophagus surveillance protocols are created equal: the dangers of retrospective outcome research in the treatment of Barrett's esophagus. Gastrointestinal Endoscopy 80(6): 1203, 2015

Barrett's esophagus: update on screening, surveillance, and treatment. Archives of Internal Medicine 159(13): 1411-1416, 1999

The field effect in Barrett's esophagus: can we use it for screening and surveillance?. Endoscopy 45(12): 989-991, 2014

Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?. Digestive Diseases and Sciences 63(8): 2094-2104, 2018

Evolving screening and surveillance techniques for Barrett's esophagus. World Journal of Gastroenterology 25(17): 2045-2057, 2019

Barrett's Esophagus: Diagnosis, Screening, Surveillance, and Controversies. Gut and Liver 1(2): 93-100, 2007

Screening and surveillance in Barrett's esophagus: a call to action. Clinical Gastroenterology and Hepatology 2(10): 861-864, 2004

Another look at Barrett's esophagus. Current thinking on screening and surveillance strategies. Postgraduate Medicine 110(3): 57-8, 61-2, 65-8, 2001

The use of optical coherence tomography in screening and surveillance of Barrett's esophagus. Clinical Gastroenterology and Hepatology 3(7 Suppl 1): S8-11, 2005

Point-Counterpoint: Screening and Surveillance for Barrett's Esophagus, Is It Worthwhile?. Digestive Diseases and Sciences: -, 2018